Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | FEB 27 | New STN AnaVist pricing effective March 1, 2006 |
| NEWS | 4 | MAY 10 | CA/CAplus enhanced with 1900-1906 U.S. patent records |
| NEWS | 5 | MAY 11 | KOREAPAT updates resume |
| NEWS | 6 | MAY 19 | Derwent World Patents Index to be reloaded and enhanced |
| NEWS | 7 | MAY 30 | IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2 |
| NEWS | 8 | MAY 30 | The F-Term thesaurus is now available in CA/CAplus |
| NEWS | 9 | JUN 02 | The first reclassification of IPC codes now complete in INPADOC |
| NEWS | 10 | JUN 26 | TULSA/TULSA2 reloaded and enhanced with new search and and display fields |
| NEWS | 11 | JUN 28 | Price changes in full-text patent databases EPFULL and PCTFULL |
| NEWS | 12 | JUl 11 | CHEMSAFE reloaded and enhanced |
| NEWS | 13 | JUl 14 | FSTA enhanced with Japanese patents |
| NEWS | 14 | JUl 19 | Coverage of Research Disclosure reinstated in DWPI |
| NEWS | 15 | AUG 09 | INSPEC enhanced with 1898-1968 archive |
| NEWS | 16 | AUG 28 | ADISCTI Reloaded and Enhanced |
| NEWS | 17 | AUG 30 | CA(SM)/CAplus(SM) Austrian patent law changes |
| NEWS | 18 | SEP 11 | CA/CAplus enhanced with more pre-1907 records |

| | |
|---|---|
| NEWS EXPRESS | JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006. |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |
| NEWS X25 | X.25 communication option no longer available |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4
DICTIONARY FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer
be available. Please contact CAS Customer Care
(http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> e oxamflatin/cn
E1            1     OXAMETHONIUM/CN
E2            1     OXAMETHONIUM IODIDE/CN
E3            1 --> OXAMFLATIN/CN
E4            1     OXAMIC ACID/CN
E5            1     OXAMIC ACID AMIDE/CN
E6            1     OXAMIC ACID CHLORIDE/CN
E7            1     OXAMIC ACID HYDRAZIDE/CN
E8            1     OXAMIC ACID, (((CARBOXYMETHYL)CARBAMOYL)METHYL)-/CN
E9            1     OXAMIC ACID, ((3-AMINOPYRAZINYL)METHYL)-, ETHYL ESTER/CN
E10           1     OXAMIC ACID, ((4-AMINO-2-ETHYL-5-PYRIMIDINYL)METHYL)-/CN
E11           1     OXAMIC ACID, ((4-AMINO-2-ETHYL-5-PYRIMIDINYL)METHYL)-, ETHYL
                     ESTER/CN
E12           1     OXAMIC ACID, ((4-AMINO-2-ETHYL-5-PYRIMIDINYL)METHYL)THIO- ((
                    C7H10N3)NHCSCOOH)/CN

=> e3
L1            1 OXAMFLATIN/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   151720-43-3  REGISTRY
ED   Entered STN:  14 Dec 1993
CN   2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (E)-
OTHER NAMES:
CN   Oxamflatin
FS   STEREOSEARCH
MF   C17 H14 N2 O4 S
```

SR CA
LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, EMBASE, PROUSDDR, TOXCENTER, USPAT2, USPATFULL

Double bond geometry as shown.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

56 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
57 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 7.10 | 7.31 |

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> l1
L2 57 L1

=> d l2 47-57 ti

L2 ANSWER 47 OF 57 CAPLUS 

TI Inhibition of histone deacetylase as a treatment for cardiac hypertrophy

L2 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase

L2 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

L2 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms

L2 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of treating autoimmune diseases with histone hyperacetylating agent

L2 ANSWER 52 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Chemical inducers for morphological reversion of oncogenically transformed NIH3T3 cells

L2 ANSWER 53 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI The novel anti-tumor agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity

L2 ANSWER 54 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

L2 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD

L2 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI (2E)-5-[3-[(Phenylsulfonyl)amino]phenyl]- pent-2-en-4-ynohydroxamic Acid and Its Derivatives as Novel and Potent Inhibitors of ras Transformation

L2 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors

=> d l2 57 ti fbib abs

L2 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors
AN 1994:54333 CAPLUS
DN 120:54333
TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors
IN Ohtani, Mitsuaki; Arita, Hitoshi; Sugita, Kenji; Matsuura, Takaharu; Shirahase, Kazuhiro
PA Shionogi and Co., Ltd., Japan
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9312075 | A1 | 19930624 | WO 1992-JP1593 | 19921207 |

W: JP, KR, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | JP 1991-350793 | A | 19911210 |
| EP 570594 | A1 | 19931124 | | EP 1992-924883 | | 19921207 |
| EP 570594 | B1 | 19970730 | | | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | JP 1991-350793 | A | 19911210 |
| | | | | WO 1992-JP1593 | W | 19921207 |
| AT 156116 | E | 19970815 | | AT 1992-924883 | | 19921207 |
| | | | | JP 1991-350793 | A | 19911210 |
| ES 2107557 | T3 | 19971201 | | ES 1992-924883 | | 19921207 |
| | | | | JP 1991-350793 | A | 19911210 |
| JP 3342485 | B2 | 20021111 | | JP 1993-510775 | | 19921207 |
| | | | | JP 1991-350793 | A | 19911210 |
| | | | | WO 1992-JP1593 | W | 19921207 |
| US 5534654 | A | 19960709 | | US 1993-98272 | | 19930803 |
| | | | | JP 1991-350793 | A | 19911210 |
| | | | | WO 1992-JP1593 | W | 19921207 |

OS MARPAT 120:54333
GI

Q= 





II




III

AB The title compds. R2ONR1COXA1YNR3BA2 (I) [A1 = (substituted) aromatic ring, aromatic heterocyclic ring; A2 = H, (substituted) aryl, aromatic heterocyclic ring; B = single bond, B1B2; B1 = CO, SO2; B2 = alkylene, alkenylene, etc.; X = (substituted) alkylene which may have O, S, N and may have unsatd. bond; Y = single bond, heteroatom, (substituted) alkylene which may contain heteroatom and may have unsatd. bond; X and N (which is linked to Y) may together form a moiety Q; R1 - R3 = H, (substituted) alkyl, aryl] were prepared I inhibit hemangioendothelial cell growth, the development of a lymphocyte adhesion factor, and ras gene-induced cell transformation and are useful as inflammation and tumor inhibitors. Condensation of carboxylic acid (E)-II (R = OH) with NH2OH.HCl in DMF containing N-hydroxysuccinimide, N,N-dicyclohexylcarbodiimide, and Et3n gave (E)-II (R = NHOH). Hydroxamic acid (E)-III in vitro exhibited MIC of 0.039 μM against ras gene-induced cell transformation.

=> sodium (l)transport
1060363 SODIUM
35 SODIUMS
1060372 SODIUM
(SODIUM OR SODIUMS)
708922 TRANSPORT
5830 TRANSPORTS
711245 TRANSPORT
(TRANSPORT OR TRANSPORTS)

```
L3       43283 SODIUM (L)TRANSPORT

=> l2 and l3
L4           1 L2 AND L3

=> d l4 ti fbi abs
'FBI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
```

specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d l4 ti fbib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms
AN 2002:539823 CAPLUS
DN 137:103874
TI Histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms
IN Fojo, Antonio Tito; Bates, Susan Elaine
PA The Government of the United States of America, Department of Health & Human Services, USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2002055688 | A2 | 20020718 | WO 2002-US714 | | 20020108 |
| | WO 2002055688 | A3 | 20030410 | | | |
| | WO 2002055688 | C1 | 20030925 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2001-260733P | P | 20010110 |
| | CA 2434269 | AA | 20020718 | CA 2002-2434269 | | 20020109 |
| | | | | US 2001-260733P | P | 20010110 |
| | | | | WO 2002-US714 | W | 20020109 |
| | EP 1356053 | A2 | 20031029 | EP 2002-718823 | | 20020109 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| | | | | US 2001-260733P | P | 20010110 |
| | | | | WO 2002-US714 | W | 20020108 |
| | JP 2005507231 | T2 | 20050317 | JP 2002-556736 | | 20020109 |
| | | | | US 2001-260733P | P | 20010110 |
| | | | | WO 2002-US714 | W | 20020109 |
| | US 2004132643 | A1 | 20040708 | US 2004-250320 | | 20040102 |
| | | | | WO 2002-US714 | W | 20020108 |

AB Disclosed herein are novel approaches to thyroid cancer therapy. These approaches include methods to enhance thyroid specific gene expression, for example methods to enhance expression of thyroglobulin and/or the Na+/I- symporter in thyroid cancer cells. Enhanced expression of thyroid-specific genes promotes cellular differentiation and reduces biol. aggressive behavior such as invasion and metastasis. In addition, enhanced expression of thyroglobulin and/or the Na+/I- symporter increases the ability of thyroid cancer cells to concentrate iodine or iodide, thereby making the cells more susceptible to radioactive iodine therapy. Also disclosed herein are methods for detecting thyroid neoplasms in a subject, by

administering a therapeutically effective amount of a histone deacetylase inhibitor, administering a detectable agent whose uptake or concentration in thyroid cells is increased by administration of the histone deacetylase inhibitor, and detecting the detectable agent.

=> d l4 it

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
IT Thyroid gland, neoplasm
(anaplastic carcinoma; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Hydroxamic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bis-; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Diagnosis
Diagnosis
(cancer; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Thyroid gland
(carcinoma metastasis; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Thyroid gland, neoplasm
(carcinoma, insular and residual; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Hydroxamic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs.; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Thyroid gland, neoplasm
(follicular cell carcinoma; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Antitumor agents
Chemotherapy
Radiotherapy
Thyroid gland, neoplasm
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Antisense oligonucleotides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Thyroid gland, neoplasm
(papillary carcinoma; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sodium-iodine pump, enhancing expression of; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Carcinoma
(thyroid anaplastic; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Carcinoma
(thyroid follicular cell; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

IT Carcinoma
(thyroid papillary; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Carcinoma
(thyroid, insular and residual; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thyroid-specific, activation of; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thyroid-specific, enhancing expression of; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Surgery
Thyroid gland
(thyroidectomy; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT Biological transport
(uptake; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 209783-80-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MS 27-275; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 9076-57-7, Histone deacetylase 20461-54-5, Iodide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 7553-56-2, Iodine, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 14158-31-7, 125I, biological studies 15715-08-9, 123I, biological studies
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 10043-66-0, 131I, biological studies
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 55-21-0, Benzamide 55-21-0D, Benzamide, derivs. 64-19-7D, Acetic acid, salts 107-92-6, Butyric acid, biological studies 107-92-6D, Butyric acid, salt 18992-11-5, Azelaic Bishydroxamic acid 25974-99-6, m-Carboxycinnamic acid 38937-66-5 42002-26-6 53342-16-8, Chlamydocin 58880-19-6, Trichostatin A 83209-65-8, HC-toxin 86402-37-1, WF-3161 128517-07-7, FR901228 133155-89-2, Trapoxin A 133155-90-5, Trapoxin B 139508-73-9, Depudecin 149647-78-9 151720-43-3, Oxamflatin 170720-16-8, Tan-1746 183506-66-3 183506-66-3D, analogs
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 14797-73-0, Perchlorate 23288-61-1
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(radiolabeled; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)
IT 442705-90-0 442705-91-1 442705-92-2

RL: PRP (Properties)
(unclaimed nucleotide sequence; histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms)

=> 151720-43-3
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6 57 L5

=> display hitstr l6 1-3

L6 ANSWER 1 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
IT INDEXING IN PROGRESS
IT 151720-43-3, Oxamflatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HDAC inhibitor; HDAC inhibitors that promote BRM expression, methods for their identification, and their use in cancer treatment)
RN 151720-43-3 CAPLUS
CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




L6 ANSWER 2 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
IT 151720-43-3, Oxamflatin
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition for enhancing therapeutic effects of radiotherapy and chemotherapy on tumor)
RN 151720-43-3 CAPLUS
CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 3 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN
IT 151720-43-3, Oxamflatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biol. response modifier and β-cell growth factor for restoring β-cell mass and function)
RN 151720-43-3 CAPLUS
CN 2-Penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> logoff hold

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 9.52 | 41.19 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | 0.00 | -1.50 |

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:16:08 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

```
LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 09:39:39 ON 21 SEP 2006
FILE 'CAPLUS' ENTERED AT 09:39:39 ON 21 SEP 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      9.52      41.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                        ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -1.50

=> d his

     (FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006
                E OXAMFLATIN/CN
L1             1 E3

     FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006
L2            57 L1
L3         43283 SODIUM (L)TRANSPORT
L4             1 L2 AND L3
                S 151720-43-3/REG#

     FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006
L5             1 S 151720-43-3/RN

     FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006
L6            57 S L5

=> lung
        186355 LUNG
         43168 LUNGS
L7      200642 LUNG
                (LUNG OR LUNGS)

=> l6 and l7
L8            10 L6 AND L7

=> d l8 1-10 ti

L8   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Use of thioredoxin measurements for diagnostics and treatments

L8   ANSWER 2 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Use of thioredoxin measurements for diagnostics and treatments

L8   ANSWER 3 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Method using histone deacetylase inhibitors for increasing therapeutic
     gain in radiotherapy and chemotherapy

L8   ANSWER 4 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Formulation comprising histone deacetylase inhibitor exhibiting biphasic
     release

L8   ANSWER 5 OF 10  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Methods of NAD+-dependent deacetylase inhibitors
```

L8 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination methods of treating cancer

L8 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI The Epigenome as a Target for Cancer Chemoprevention

L8 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease

L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of treating TRX mediated diseases by administering histone deacetylase inhibitors

L8 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

=> d l8 1-10 ti fbib abs

L8 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of thioredoxin measurements for diagnostics and treatments
AN 2005:1355554 CAPLUS
DN 144:81158
TI Use of thioredoxin measurements for diagnostics and treatments
IN Marks, Paul A.; Ungerstedt, Johanna
PA USA
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 369,094.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | US 2005288227 | A1 | 20051229 | US 2005-144301 | | 20050603 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | US 2003-369094 | A2 | 20030214 |
| | | | | US 2004-577089P | P | 20040604 |
| | US 2003235588 | A1 | 20031225 | US 2003-369094 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | US 2006009526 | A1 | 20060112 | US 2005-223405 | | 20050909 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | US 2003-369094 | B1 | 20030214 |
| | US 2006009527 | A1 | 20060112 | US 2005-223547 | | 20050909 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | US 2003-369094 | B1 | 20030214 |

PATENT FAMILY INFORMATION:
FAN 2003:678618

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2003070188 | A2 | 20030828 | WO 2003-US4924 | 20030214 |
| | WO 2003070188 | A3 | 20040219 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-357383P P 20020215
CA 2476434 AA 20030828 CA 2003-2476434 20030214
US 2002-357383P P 20020215
WO 2003-US4924 W 20030214
AU 2003219803 A1 20030909 AU 2003-219803 20030214
US 2002-357383P P 20020215
WO 2003-US4924 W 20030214
EP 1482962 A2 20041208 EP 2003-716078 20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2002-357383P P 20020215
WO 2003-US4924 W 20030214
JP 2005525345 T2 20050825 JP 2003-569148 20030214
US 2002-357383P P 20020215
WO 2003-US4924 W 20030214
AU 2005227400 A1 20051117 AU 2005-227400 20051028
AU 2003-219803 A3 20030214
WO 2003-US4924 W 20030214

FAN 2005:1313861

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005117930 | A2 | 20051215 | WO 2005-US19523 | 20050603 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004-577089P P 20040604

AB The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.

L8 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of thioredoxin measurements for diagnostics and treatments
AN 2005:1313861 CAPLUS
DN 144:45450
TI Use of thioredoxin measurements for diagnostics and treatments
IN Marks, Paul A.; Ungerstedt, Johanna
PA Sloan-Kettering Institute for Cancer Research, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005117930 | A2 | 20051215 | WO 2005-US19523 | 20050603 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004-577089P P 20040604

PATENT FAMILY INFORMATION:

FAN 2003:678618

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2003070188 | A2 | 20030828 | WO 2003-US4924 | | 20030214 |
| | WO 2003070188 | A3 | 20040219 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2002-357383P | P | 20020215 |
| | CA 2476434 | AA | 20030828 | CA 2003-2476434 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | AU 2003219803 | A1 | 20030909 | AU 2003-219803 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | EP 1482962 | A2 | 20041208 | EP 2003-716078 | | 20030214 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | JP 2005525345 | T2 | 20050825 | JP 2003-569148 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | AU 2005227400 | A1 | 20051117 | AU 2005-227400 | | 20051028 |
| | | | | AU 2003-219803 | A3 | 20030214 |
| | | | | WO 2003-US4924 | W | 20030214 |

FAN 2005:1355554

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | US 2005288227 | A1 | 20051229 | US 2005-144301 | | 20050603 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | US 2003-369094 | A2 | 20030214 |
| | | | | US 2004-577089P | P | 20040604 |
| | US 2003235588 | A1 | 20031225 | US 2003-369094 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | US 2006009526 | A1 | 20060112 | US 2005-223405 | | 20050909 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | US 2003-369094 | B1 | 20030214 |
| | US 2006009527 | A1 | 20060112 | US 2005-223547 | | 20050909 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | US 2003-369094 | B1 | 20030214 |

AB The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid

(SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.

L8 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method using histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
AN 2005:1292833 CAPLUS
DN 144:32206
TI Method using histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
IN Chung, Yih-Lin
PA Taiwan
SO U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 205,738.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2005272644 | A1 | 20051208 | US 2004-798119 | 20040311 |
| | | | | US 2002-205738 A2 | 20020725 |
| | US 2004018958 | A1 | 20040129 | US 2002-205738 | 20020725 |
| | US 6809118 | B2 | 20041026 | | |

PATENT FAMILY INFORMATION:
FAN 2004:80330

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2004018958 | A1 | 20040129 | US 2002-205738 | 20020725 |
| | US 6809118 | B2 | 20041026 | | |
| | EP 1574213 | A1 | 20050914 | EP 2004-5807 | 20040311 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | | | | US 2002-205738 A | 20020725 |
| | US 2005272644 | A1 | 20051208 | US 2004-798119 | 20040311 |
| | | | | US 2002-205738 A2 | 20020725 |
| | JP 2005281150 | A2 | 20051013 | JP 2004-93861 | 20040326 |
| | | | | US 2002-205738 A | 20020725 |

AB The invention provides compns. and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compds. are capable of simultaneously stimulating epithelial regrowth, inhibiting fibroblast proliferation, decreasing collagen deposits, suppressing fibrogenic growth factor, subsiding proinflammatory cytokine, and modulating expression of cell cycle genes, tumor suppressors and oncogenes, and are useful for increasing the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelial healing in mucosa and dermis, decrease of xerostomia, prevention/reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

L8 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release

AN 2005:1168848 CAPLUS
DN 143:446691
TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
IN Franke, Hanshermann; Lennartz, Peter; Maurer, Alexander, B.; Hentsch, Bernd; Hoevelmann, Sascha; Martin, Elke
PA G2M Cancer Drugs A.-G., Germany; Desitin Arzneimittel G.m.b.H.
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 1591109 | A1 | 20051102 | EP 2004-10333 | 20040430 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | WO 2005105055 | A1 | 20051110 | WO 2005-EP4739 | 20050502 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

EP 2004-10333 A 20040430

OS MARPAT 143:446691
AB The present invention relates to an orally available galenics formulation of Valproic Acid or derivs. thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum inhibition of histone deacetylases in a therapeutic setting. This specific galenics formulation is designed for the treatment of malignant diseases and diseases associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect, e.g., by induction of differentiation and/or apoptosis. Due to the bi-phasic release pattern the resulting pharmacokinetic profile is able to inhibit HDAC target enzymes most efficiently and to subsequently induce histone hyperacetylation in a rapid as well as a long-lasting fashion. This profile secures the efficient modulation of a desired target gene expression profile which contributes to the therapeutic benefit.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of NAD+-dependent deacetylase inhibitors
AN 2005:523233 CAPLUS
DN 143:53553
TI Methods of NAD+-dependent deacetylase inhibitors
IN Zhang, Jie; Xu, Weizheng
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2005053609 | A2 | 20050616 | WO 2004-US39220 | 20041123 |

WO 2005053609 A3 20050901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003-525303P P 20031126
OS MARPAT 143:53553
GI



I



II



III

AB The present invention relates to methods of treating cancer, cardiovascular disorders, and neurol. disorders using NAD+-dependent deacetylase Sir2 inhibitors. The present invention also relates to a method comprising administering an effective amount of a NAD+-dependent deacetylase inhibitor and a Type I or Type II histone deacetylase inhibitor to treat cancer. The present invention involves a method of an effective amount of a NAD+-dependent deacetylase inhibitor to treat cancer wherein said SIR2 inhibitor can be a compound of formula I, wherein X is O, N, S, P, C=O; A is a bond, H, CH2, CHR8, -CH2-NH-, -CHR8-NH-, -CH2-NR8-, -(CH2)2-, -CH2-CHR8-; B is C, N, S, C-A, N-A, S-A; and R1, R2, R3, R4, R5, R6, R7, R8, R9 can be an optionally substituted H, F, Cl, Br, I, amino, hydroxy, -N-N, -CO-N-N, halogen-substituted amino, -O-alkyl, -O-aryl, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc. The NAD+-dependent deacetylase inhibitor can also be formula II wherein X is O, N, S, P; A is O, S, S=O, SO2, CH2, CHR9, -CH2-NH-, -CHR9-NH-, -CH2-NR9-, -(CH2)2-, -CH2-CHR9-; and R1, R2, R3, R4, R5, R6, R7, R8, R9 can be an optionally substituted H, F, Cl, Br, I, amino, hydroxy, -N-N, -CO-N-N, halogen-substituted amino, -O-alkyl, -O-aryl, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc. In addition, the

NAD+-dependent deacetylase inhibitor can be formula III wherein X is O, N, S, P; and R1, R2, R3, R4, R5, R6 is an optionally substituted H, F, Cl, Br, I, amino, hydroxy, -N-N, -CO-N-N, halogen-substituted amino, -O-alkyl, -O-aryl, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

L8 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination methods of treating cancer
AN 2005:232565 CAPLUS
DN 142:309871
TI Combination methods of treating cancer
IN Bacopoulos, Nicholas G.; Chiao, Judy H.; Marks, Paul A.; Miller, Thomas A.; Paradise, Carolyn M.; Richon, Victoria M.; Rifkind, Richard A.
PA Aton Pharma, Inc., USA; Sloan-Kettering Institute for Cancer Research
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2005023179 | A2 | 20050317 | WO 2004-US26161 | | 20040812 |
| | WO 2005023179 | A3 | 20050616 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2003-498803P | P | 20030829 |
| | AU 2004270150 | A2 | 20050317 | AU 2004-270150 | | 20040812 |
| | AU 2004270150 | A1 | 20050317 | | | |
| | | | | US 2003-498803P | P | 20030829 |
| | | | | WO 2004-US26161 | W | 20040812 |
| | CA 2535889 | AA | 20050317 | CA 2004-2535889 | | 20040812 |
| | | | | US 2003-498803P | P | 20030829 |
| | | | | WO 2004-US26161 | W | 20040812 |
| | EP 1667680 | A2 | 20060614 | EP 2004-780925 | | 20040812 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | | |
| | | | | US 2003-498803P | P | 20030829 |
| | | | | WO 2004-US26161 | W | 20040812 |

OS MARPAT 142:309871
AB The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amts. together comprise a therapeutically effective amount The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

L8 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI The Epigenome as a Target for Cancer Chemoprevention
AN 2003:983640 CAPLUS
DN 141:16551
TI The Epigenome as a Target for Cancer Chemoprevention
AU Kopelovich, Levy; Crowell, James A.; Fay, Judith R.

CS National Cancer Institute, Chemopreventive Agent Development Research Group, National Institutes of Health, Bethesda, MD, USA
SO Journal of the National Cancer Institute (2003), 95(23), 1747-1757
CODEN: JNCIEQ; ISSN: 0027-8874
PB Oxford University Press
DT Journal; General Review
LA English
AB A review. Epigenetic events, a key driving force in the development of cancer, are alterations in gene expression without changes in the DNA coding sequence that are heritable through cell division. Such changes occur throughout all stages of tumorigenesis, including the early phases, and are increasingly recognized as major mechanisms involved in silencing tumor suppressor genes. Epigenetic changes can be reversed by the use of small mols. and, thus, such changes are promising targets for cancer chemopreventive drug development. This review examines the basis for targeting the epigenome as a prevention strategy, focusing on understanding the epigenetic changes that occur before the development of frank malignancy, when chemopreventive intervention will have the maximal impact.
RE.CNT 121 THERE ARE 121 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease
AN 2003:796863 CAPLUS
DN 139:286376
TI Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease
IN Dangond, Fernando
PA Brigham and Women's Hospital, Inc., USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2003083067 | A2 | 20031009 | WO 2003-US9273 | 20030327 |
| WO 2003083067 | C1 | 20040819 | | |
| WO 2003083067 | A3 | 20050324 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | US 2002-368228P P | 20020328 |
| | | | US 2002-404664P P | 20020820 |
| AU 2003226014 | A1 | 20031013 | AU 2003-226014 | 20030327 |
| | | | US 2002-368228P P | 20020328 |
| | | | US 2002-404664P P | 20020820 |
| | | | WO 2003-US9273 W | 20030327 |
| US 2004077591 | A1 | 20040422 | US 2003-401274 | 20030327 |
| | | | US 2002-368228P P | 20020328 |
| | | | US 2002-404664P P | 20020820 |

AB The present invention provide therapies for Alzheimer's disease (AD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The method relies on the use of an HDAC inhibitor, alone or in combination

with other drugs, to prevent or treat AD, MS or ALS. Also provided are methods of screening for addnl. HDAC inhibitors with particular efficacy against these disease states. Modulation of expression of genes, involved in neuroprotection and immune regulation, by HDAC inhibitors were demonstrated.

L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of treating TRX mediated diseases by administering histone deacetylase inhibitors
AN 2003:678618 CAPLUS
DN 139:207775
TI Method of treating TRX mediated diseases by administering histone deacetylase inhibitors
IN Richon, Victoria M.; Marks, Paul A.; Rifkind, Richard A.; Butler, Lisa M.
PA Sloan-Kettering Institute for Cancer Research, USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2003070188 | A2 | 20030828 | WO 2003-US4924 | | 20030214 |
| | WO 2003070188 | A3 | 20040219 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2002-357383P | P | 20020215 |
| | CA 2476434 | AA | 20030828 | CA 2003-2476434 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | AU 2003219803 | A1 | 20030909 | AU 2003-219803 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | EP 1482962 | A2 | 20041208 | EP 2003-716078 | | 20030214 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | JP 2005525345 | T2 | 20050825 | JP 2003-569148 | | 20030214 |
| | | | | US 2002-357383P | P | 20020215 |
| | | | | WO 2003-US4924 | W | 20030214 |
| | AU 2005227400 | A1 | 20051117 | AU 2005-227400 | | 20051028 |
| | | | | AU 2003-219803 | A3 | 20030214 |
| | | | | WO 2003-US4924 | W | 20030214 |

PATENT FAMILY INFORMATION:
FAN 2005:1313861

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2005117930 | A2 | 20051215 | WO 2005-US19523 | | 20050603 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, | | | | | |

ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004-577089P P 20040604

FAN 2005:1355554

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| PI US 2005288227 | A1 | 20051229 | US 2005-144301 | | 20050603 |
| | | | US 2002-357383P | P | 20020215 |
| | | | US 2003-369094 | A2 | 20030214 |
| | | | US 2004-577089P | P | 20040604 |
| US 2003235588 | A1 | 20031225 | US 2003-369094 | | 20030214 |
| | | | US 2002-357383P | P | 20020215 |
| US 2006009526 | A1 | 20060112 | US 2005-223405 | | 20050909 |
| | | | US 2002-357383P | P | 20020215 |
| | | | US 2003-369094 | B1 | 20030214 |
| US 2006009527 | A1 | 20060112 | US 2005-223547 | | 20050909 |
| | | | US 2002-357383P | P | 20020215 |
| | | | US 2003-369094 | B1 | 20030214 |

OS MARPAT 139:207775

AB The invention provides a novel method for treating and/or preventing thioredoxin (TRX)-mediated diseases and conditions, by administering to a subject in need of such treatment a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof. The HDAC inhibitor can alter the expression of a thioredoxin-binding-protein (e.g. TBP-2), which in turn can lead to an altered TRX/thioredoxin-binding-protein cellular binding interaction, resulting in an increase or decrease in the level or activity of cellular TRX, for example the expression level or reducing activity of TRX. Thus the invention relates to the use of HDAC inhibitors in a method of preventing and/or treating a wide variety of thioredoxin (TRX)-mediated diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.

L8 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors
AN 2002:736103 CAPLUS
DN 137:247516
TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors
IN Naka, Masao; Takahashi, Kanji
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002074298 | A1 | 20020926 | WO 2002-JP2681 | 20020320 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| | | | JP 2001-81302 | A | 20010321 |
| US 2005119305 | A1 | 20050602 | US 2003-472160 | | 20030922 |
| | | | JP 2001-81302 | A | 20010321 |
| | | | WO 2002-JP2681 | W | 20020320 |

OS MARPAT 137:247516

GI



I

AB Interleukin 6 (IL-6) production inhibitors containing as the active ingredient hydroxamic acid derivs. (I) or equivalent thereto, non-toxic salts thereof or prodrugs of the same [R1 = C1-8 alkyl, C2-8 alkenyl or alkynyl, halo, NO2, cyano, CF3, CF3O, OR2, SR2, NR3R4, keto, cyclic group, COR5, SO2R10, SOR10, etc.(wherein R2-R4 = H, C1-8 alkyl, C2-9 acyl, cyclic group; R5 = HO, C1-8 alkyl or alkoxy, optionally substituted NH2, cyclic group; R10 = C1-8 alkyl, cyclic group); A = single bond, C3-15 mono-, di-, or tricyclic carbocyclic ring, 5- to 18-membered mono, di-, or tricyclic heterocyclic ring containing 1-4 N, 1-2 O and/or 1-2 S atoms; E = a single bond, C1-8 alkylene, C2-8 alkenylene or alkynylene, O, SO2NH, NHSO2, CONH, NHCO, etc.; B = s single bond, C5-15 mono-, di-, or tricyclic carbocyclic ring; 5- to 18-membered mono-, di-, or tricyclic heterocyclic ring containing 1-4 N, 1-2 O and/or 1-2 S atoms; R8 = C1-8 alkyl or alkoxy, halo, NO2, cyano, CF3, CF3O, HO, C1-8 hydroxyalkyl; when E is a single bond, R1 and R8 together represents a C1-4 alkylene; n = an integer of 1-5; G = a single bond, (un)substituted NHCO or CONH, O, S, SO, SO2, (un)substituted SO2NH, CO, etc.; L = C1-8 alkylene, C2-8 alkenylene or alkynylene, C2-8 alkenylene-C2-8 alkynylene, C2-8 alkylene-C2-8 alkenylene, etc.; Q = (un)substituted CONHOH, oxiranylcarbonyl, (un)substituted SH, P(O)(OH)2 or its C1-4 alkyl ester; some proviso are given] are claimed. Because of having an IL-6 production inhibitory activity, the compds. of the general formula I are useful as preventives and/or remedies for various inflammatory diseases, sepsis, multiple myeloma, plasmacytoid leukemia, osteoporosis, cachexia, psoriasis, nephritis, kidney cell cancer, Kaposi's sarcoma, rheumatoid arthritis, hypergamma globulinemia, Castleman's disease, intra-atrial myxoma, diabetes, autoimmune diseases, hepatitis, colitis, graft-vs.-host disease, infections, endometriosis and solid cancer. The solid cancer include brain tumor, head and neck cancer, thyroid gland cancer, esophageal cancer, stomach cancer, colorectal cancer (colon cancer and rectum cancer), liver cancer, gallbladder cancer, bile duct cancer (cholangioma), pancreatic cancer, lung cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, prostatic cancer, testicular tumor, bladder cancer, renal pelvis tumor, ureteral tumor, adrenal cancer (hypernephroma), neuroma, glioma, bone tumor, rhabdomyosarcoma, osteosarcoma, soft tissue tumor, eosinophilic granuloma, malignant melanoma, skin cancer, Wilms's tumor, etc. Thus, to a solution of 2.24 g 6-[(4-phenylbenzoyl)amino]hexanoic acid in 42 mL DMF were successively added 1-hydroxybenzotriazole hydrate 1.65, Et3N 2.91, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 2.07, and N-(1-methyl-1-methoxyethoxy)amine 1.14 g and stirred at room temperature for 4 h

to give 1.79 g N-(1-methyl-1-methoxyethoxy)-6-[(4-phenylbenzoyl)amino]hexanamide which (1.78 g) was dissolved in 4.5 m MeOH and stirred with 4.5 mL 2 N aqueous HCl at room temperature to give N-hydroxy-6-[(4-phenylbenzoyl)amino]hexanamide (II). II in vitro inhibited the production of IL-6 in human lung epithelial cell A549

```
     with IC50 of 0.18 μM.  A tablet and an ampule formulation containing II
     were prepared
RE.CNT  27    THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> hydoxam?
L9            7 HYDOXAM?

=> hydroxam?
L10       10111 HYDROXAM?

=> d his

     (FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006
                E OXAMFLATIN/CN
L1             1 E3

     FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006
L2            57 L1
L3         43283 SODIUM (L)TRANSPORT
L4             1 L2 AND L3
                 S 151720-43-3/REG#

     FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006
L5             1 S 151720-43-3/RN

     FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006
L6            57 S L5
L7        200642 LUNG
L8            10 L6 AND L7
L9             7 HYDOXAM?
L10        10111 HYDROXAM?

=> l3(l)l10
L11           9 L3(L)L10

=> d l11 1-9 ti

L11  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Detection of an FeL2 Complex of Ferrioxamine B and Determination of Its
     Stability Constant in Aqueous Micellar SDS

L11  ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   A preparation of unsaturated hydroxamic acid derivatives useful as histone
     deacetylase inhibitors

L11  ANSWER 3 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Glutamate-induced inhibition of D-aspartate uptake in mueller glia from
     the retina

L11  ANSWER 4 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Characterization of cystine uptake in cultured astrocytes

L11  ANSWER 5 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Regulation of high-affinity glutamate uptake activity in Bergmann glia
     cells by glutamate

L11  ANSWER 6 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Accumulation of extracellular glutamate by inhibition of its uptake is not
     sufficient for inducing neuronal damage: an in vivo microdialysis study
```

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
TI Comparative analysis of sodium-dependent L-glutamate transport of synaptosomal and astroglial membrane vesicles from mouse cortex

L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
TI Chiral linear hydroxamates as biomimetic analogs of ferrioxamine and coprogen and their use in probing siderophore-receptor specificity in bacteria and fungi

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
TI Iron-dependent production of hydroxamate by sodium-dependent Azotobacter chroococcum

=> d l11 2 ti fbib abs

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors
AN 2004:453179 CAPLUS
DN 141:23197
TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors
IN Wiech, Norbert L.; Lan-Hargest, Hsuan-yin
PA Circagen Pharmaceutical, USA; Beacon Laboratories
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2004046104 | A2 | 20040603 | WO 2003-US36981 | 20031119 |
| WO 2004046104 | A3 | 20040805 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | US 2002-427567P | P 20021120 |
| CA 2506504 | AA | 20040603 | CA 2003-2506504 | 20031119 |
| | | | US 2002-427567P | P 20021120 |
| | | | WO 2003-US36981 | W 20031119 |
| AU 2003291097 | A1 | 20040615 | AU 2003-291097 | 20031119 |
| | | | US 2002-427567P | P 20021120 |
| | | | WO 2003-US36981 | W 20031119 |
| EP 1567142 | A2 | 20050831 | EP 2003-783686 | 20031119 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | | | US 2002-427567P | P 20021120 |
| | | | WO 2003-US36981 | W 20031119 |
| JP 2006508986 | T2 | 20060316 | JP 2004-553939 | 20031119 |
| | | | US 2002-427567P | P 20021120 |
| | | | WO 2003-US36981 | W 20031119 |

PATENT FAMILY INFORMATION:
FAN 2002:754352

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | | 20020325 |
| | WO 2002076941 | A3 | 20040212 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2001-812940 | A1 | 20010327 |
| | | | | US 2001-812944 | A1 | 20010327 |
| | | | | US 2001-812945 | A1 | 20010327 |
| | | | | US 2001-25947 | A1 | 20011226 |
| | US 2002143196 | A1 | 20021003 | US 2001-812944 | | 20010327 |
| | US 6495719 | B2 | 20021217 | | | |
| | US 2002143052 | A1 | 20021003 | US 2001-812945 | | 20010327 |
| | US 2002143037 | A1 | 20021003 | US 2001-25947 | | 20011226 |
| | | | | US 2001-812940 | B1 | 20010327 |
| | CA 2442366 | AA | 20021003 | CA 2002-2442366 | | 20020325 |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | AU 2002250401 | A1 | 20021008 | AU 2002-250401 | | 20020325 |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | EP 1408946 | A2 | 20040421 | EP 2002-719311 | | 20020325 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |

FAN 2002:755220

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | US 2002143052 | A1 | 20021003 | US 2001-812945 | | 20010327 |
| | CA 2442366 | AA | 20021003 | CA 2002-2442366 | | 20020325 |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | | 20020325 |
| | WO 2002076941 | A3 | 20040212 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, | | | | | |

GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| | | | US 2001-812940 | A1 20010327 |
| | | | US 2001-812944 | A1 20010327 |
| | | | US 2001-812945 | A1 20010327 |
| | | | US 2001-25947 | A1 20011226 |
| AU 2002250401 | A1 | 20021008 | AU 2002-250401 | 20020325 |
| | | | US 2001-812940 | A 20010327 |
| | | | US 2001-812944 | A 20010327 |
| | | | US 2001-812945 | A 20010327 |
| | | | US 2001-25947 | A 20011226 |
| | | | WO 2002-US8836 | W 20020325 |
| EP 1408946 | A2 | 20040421 | EP 2002-719311 | 20020325 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|---|---|---|---|---|
| | | | US 2001-812940 | A 20010327 |
| | | | US 2001-812944 | A 20010327 |
| | | | US 2001-812945 | A 20010327 |
| | | | US 2001-25947 | A 20011226 |
| | | | WO 2002-US8836 | W 20020325 |
| US 2003125306 | A1 | 20030703 | US 2002-318225 | 20021213 |
| | | | US 2001-812945 | A3 20010327 |
| US 2005107348 | A1 | 20050519 | US 2004-19303 | 20041223 |
| | | | US 2001-812945 | A3 20010327 |
| US 2005171208 | A1 | 20050804 | US 2005-59377 | 20050217 |
| | | | US 2001-812945 | A3 20010327 |

FAN 2002:755255

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US 2002143196 | A1 | 20021003 | US 2001-812944 | 20010327 |
| US 6495719 | B2 | 20021217 | | |
| CA 2442366 | AA | 20021003 | CA 2002-2442366 | 20020325 |
| | | | US 2001-812940 | A 20010327 |
| | | | US 2001-812944 | A 20010327 |
| | | | US 2001-812945 | A 20010327 |
| | | | US 2001-25947 | A 20011226 |
| | | | WO 2002-US8836 | W 20020325 |
| WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | 20020325 |
| WO 2002076941 | A3 | 20040212 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| | | | US 2001-812940 | A1 20010327 |
| | | | US 2001-812944 | A1 20010327 |
| | | | US 2001-812945 | A1 20010327 |
| | | | US 2001-25947 | A1 20011226 |
| AU 2002250401 | A1 | 20021008 | AU 2002-250401 | 20020325 |
| | | | US 2001-812940 | A 20010327 |
| | | | US 2001-812944 | A 20010327 |
| | | | US 2001-812945 | A 20010327 |
| | | | US 2001-25947 | A 20011226 |
| | | | WO 2002-US8836 | W 20020325 |
| EP 1408946 | A2 | 20040421 | EP 2002-719311 | 20020325 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|---|---|---|---|---|
| | | | US 2001-812940 | A 20010327 |
| | | | US 2001-812944 | A 20010327 |

| | | | | | |
|---|---|---|---|---|---|
| | | | | US 2001-812945 | A 20010327 |
| | | | | US 2001-25947 | A 20011226 |
| | | | | WO 2002-US8836 | W 20020325 |
| | US 2003083521 | A1 | 20030501 | US 2002-307321 | 20021202 |
| | | | | US 2001-812944 | A3 20010327 |

FAN 2004:701812

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2004167184 | A1 | 20040826 | US 2003-715377 | 20031119 |
| | | | | US 2001-812940 | B1 20010327 |
| | | | | US 2001-25947 | A2 20011226 |
| | | | | US 2002-427567P | P 20021120 |
| | US 2002143037 | A1 | 20021003 | US 2001-25947 | 20011226 |
| | | | | US 2001-812940 | B1 20010327 |

OS MARPAT 141:23197

GI



I

AB The invention relates to a preparation of amides of formula I [wherein: A is (hetero)cycloalk(en)yl, (hetero)aryl, etc.; Y1 and Y2 are independently selected from CH2, O, S, OC(O)O, NH, or -NHC(O)O-, etc.; L is (un)substituted C2-12 hydrocarbon chain optionally containing one double bond, at least one triple bond, or at least one double bond and one triple bond; R1 is H, alk(en/yn)yl, alkoxy, OH, etc.; R2 is H, alkyl, hydroxyalkyl, or haloalkyl, etc.], useful as histone deacetylase inhibitors. The invented compds. are claimed to be useful for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and asthma, etc. The prepared compds. were screened in cystic fibrosis assay (example 4 and 5) and for bronchial epithelial electrolyte transport (example 6). The mean inhibition of sodium transport for 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was 69.2%. Inhibition of sodium transport by 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was concentration-dependent with a half-maximal inhibitory concentration of 11.9 μM. For instance, PhCH:CHCH:CHC(O)NHOH was prepared from PhCH:CHCH:CHCO2H and NH2OH•HCl in anhydrous DMF (example 2, no yield data).

=> d his

(FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006
E OXAMFLATIN/CN
L1 1 E3

FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006
L2 57 L1
L3 43283 SODIUM (L)TRANSPORT
L4 1 L2 AND L3
S 151720-43-3/REG#

FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006
L5 1 S 151720-43-3/RN

FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006

```
L6            57 S L5
L7        200642 LUNG
L8            10 L6 AND L7
L9             7 HYDOXAM?
L10        10111 HYDROXAM?
L11            9 L3(L)L10

=> l11 and l7
L12            1 L11 AND L7

=> d l12

L12  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:453179  CAPLUS
DN   141:23197
TI   A preparation of unsaturated hydroxamic acid derivatives useful as histone
     deacetylase inhibitors
IN   Wiech, Norbert L.; Lan-Hargest, Hsuan-yin
PA   Circagen Pharmaceutical, USA; Beacon Laboratories
SO   PCT Int. Appl., 27 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2004046104        A2     20040603    WO 2003-US36981         20031119
     WO 2004046104        A3     20040805
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2506504           AA     20040603    CA 2003-2506504         20031119
     AU 2003291097        A1     20040615    AU 2003-291097          20031119
     EP 1567142           A2     20050831    EP 2003-783686          20031119
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006508986        T2     20060316    JP 2004-553939          20031119
PRAI US 2002-427567P      P      20021120
     WO 2003-US36981      W      20031119
OS   MARPAT 141:23197


=> .d his
       2359045 D
         59592 HIS
L13        245 .D HIS
                 (D(W)HIS)

=> d his

     (FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006
               E OXAMFLATIN/CN
L1             1 E3
```

```
     FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006
L2            57 L1
L3         43283 SODIUM (L)TRANSPORT
L4             1 L2 AND L3
                 S 151720-43-3/REG#

     FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006
L5             1 S 151720-43-3/RN

     FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006
L6            57 S L5
L7        200642 LUNG
L8            10 L6 AND L7
L9             7 HYDOXAM?
L10        10111 HYDROXAM?
L11            9 L3(L)L10
L12            1 L11 AND L7
L13          245 .D HIS

=> l10(l)l7
L14           85 L10(L)L7

=> lethal
          52569 LETHAL
            693 LETHALS
L15       52885 LETHAL
                  (LETHAL OR LETHALS)

=> l10(l)l15
L16           24 L10(L)L15

=> d l16  20-24 ti

L16  ANSWER 20 OF 24  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   The effects of hydroxyurea and related compounds on the rat fetus

L16  ANSWER 21 OF 24  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Pharmacological effects of anthranilohydroxamic acid and certain other
     hydroxamic acids

L16  ANSWER 22 OF 24  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   New potent reactivators of acetylcholinesterase inhibited by tetraethyl
     pyrophosphate

L16  ANSWER 23 OF 24  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Specific antidote treatment in prolonged poisoning with alkylphosphates in
     guinea pigs

L16  ANSWER 24 OF 24  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Hydroxamic acids as antitubercular agents


=> d l16 24

L16  ANSWER 24 OF 24  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   1953:42136  CAPLUS
DN   47:42136
OREF 47:7092h-i,7093a
TI   Hydroxamic acids as antitubercular agents
AU   Urbanski, T.; Hornung, S.; Slopek, S.; Venulet, J.
SO   Nature (London, United Kingdom) (1952), 170, 753-4
     CODEN: NATUAS; ISSN: 0028-0836
DT   Journal
```

LA Unavailable

=> d l16 21 ti fbib abs

L16 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmacological effects of anthranilohydroxamic acid and certain other hydroxamic acids
AN 1961:44535 CAPLUS
DN 55:44535
OREF 55:8643b-d
TI Pharmacological effects of anthranilohydroxamic acid and certain other hydroxamic acids
AU Bernheim, Frederick; Stoops, James K.
CS Duke Univ., Durham, NC
SO Proceedings of the Society for Experimental Biology and Medicine (1960), 105, 542-3
CODEN: PSEBAA; ISSN: 0037-9727
DT Journal
LA Unavailable
AB In rats, injection of anthranilohydroxamic acid, 1 mg./g. intraperitoneally, caused anesthesia lasting 10 hrs. or more. Half this dose caused tranquilization and suppression of the conditioned avoidance response. The compound protected mice against twice the lethal dose of strychnine and prolonged the life of animals given lethal doses of Metrazol or picrotoxin. In dogs, 1 g./kg. intravenously had no effect on heart rate, electrocardiogram, or blood pressure and only minor effects on respiration. Equivalent amts. of the hydroxamates of salicylic and benzoic acids had none of these effects.

=> poison?
L17 92484 POISON?

=> l10(l)l17
L18 24 L10(L)L17

=> d l18 2-0-24 ti
'2-0-24' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d l18 20-24 ti

L18 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI New potent reactivators of acetylcholinesterase inhibited by tetraethyl pyrophosphate

L18 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oximes and hydroxamic acids as antidotes in anticholinesterase poisoning

L18 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Toxicity of hydroxamic acid analogs; prophylactic and therapeutic efficacy against nerve gas poisoning in mice

L18 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Experimental chemotherapy of poisonings caused by phosphorus-containing antiesterases

L18 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI The constitution of the fulminuric acids. VIII. Metal fulminuric acid

=> d l18 22 ti fbib abs

L18 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Toxicity of hydroxamic acid analogs; prophylactic and therapeutic efficacy against nerve gas poisoning in mice
AN 1957:10194 CAPLUS
DN 51:10194
OREF 51:2169b-c
TI Toxicity of hydroxamic acid analogs; prophylactic and therapeutic efficacy against nerve gas poisoning in mice
AU Epstein, Marvin A.; Freeman, Gustave; D'Agrosa, Louis S.; Dulz, Louis
CS Army Chem. Center, MD
SO Proceedings of the Society for Experimental Biology and Medicine (1956), 92, 660-2
CODEN: PSEBAA; ISSN: 0037-9727
DT Journal
LA Unavailable
AB A series of 17 hydroxamic acid analogs were tested for toxicity and for ability to protect mice from a L.D.50 dose of Sarin. The toxicity varied over a wide range. Some protected mice against Sarin when administered in huge doses. The protective activity was unrelated to the relative toxicity.

=> d l18 9-19 ti

L18 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cyanide-insensitive oxygen uptake and pyridine nucleotide dehydrogenases in the cyanobacterium Anabaena PCC 7120

L18 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI A lead(II) ion selective electrode via a metal complex of poly(hydroxamic acid)

L18 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Structures and functions of fungal siderophores containing hydroxamate and complexone type iron binding ligands

L18 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Polymeric iron chelators

L18 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cholinesterase inhibition method for estimation of some organophosphate insecticides in forensic toxicology

L18 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Comparative protective activities of chromone-2-carbohydroxamic acid (sodium salt), methionine, and disodium tetracemate in experimental mercuric chloride poisoning in mice. Variations of lactate dehydrogenase and of its humoral and tissue isoenzymes

L18 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Iron metabolism: siderochromes

L18 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Reaction of 4-formyl-1-methylpyridinium iodide oxime with isopropyl methylphosphonofluoridate

L18 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synthesis and fungicidal activity of aryloxyalkanehydroxamic acids and analogs

L18 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI Properties and fungicidal activity of aryloxyacetohydroxamic acids

L18 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
TI The activation of the fatty acids in the liver in different experimental conditions

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 133.42 | 165.09 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -9.75 | -11.25 |

FILE 'REGISTRY' ENTERED AT 10:12:54 ON 21 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4
DICTIONARY FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> e trichostatin/cn

| | | |
|---|---|---|
| E1 | 1 | TRICHOSTATIC ACID/CN |
| E2 | 1 | TRICHOSTATIC ACID METHYL ESTER/CN |
| E3 | 1 --> | TRICHOSTATIN/CN |
| E4 | 1 | TRICHOSTATIN A/CN |
| E5 | 1 | TRICHOSTATIN A AMIDE/CN |
| E6 | 1 | TRICHOSTATIN B/CN |
| E7 | 1 | TRICHOSTATIN C/CN |
| E8 | 1 | TRICHOSTATIN D/CN |
| E9 | 1 | TRICHOSTATIN RK/CN |
| E10 | 1 | TRICHOSTIN/CN |
| E11 | 1 | TRICHOSURIN (TRICHOSURUS VULPECULA MAMMARY GLAND PRECURSOR)/CN |
| E12 | 1 | TRICHOTETROL/CN |

=> e3
L19 1 TRICHOSTATIN/CN

=> d l19

```
L19  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   119978-65-3  REGISTRY
ED   Entered STN:  07 Apr 1989
CN   Trichostatin (9CI)  (CA INDEX NAME)
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   AGRICOLA, BIOSIS, CA, CAPLUS, CIN, TOXCENTER, USPAT2,
       USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
              57 REFERENCES IN FILE CA (1907 TO DATE)
               3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              58 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> fiole caplus
             0 FIOLE
             0 CAPLUS
L20          0 FIOLE CAPLUS
                 (FIOLE(W)CAPLUS)

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    17.06     182.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -11.25

FILE 'CAPLUS' ENTERED AT 10:14:03 ON 21 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Sep 2006  VOL 145 ISS 13
FILE LAST UPDATED: 20 Sep 2006  (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> l19
L21          58 L19

=> d his

     (FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006
```

```
                E OXAMFLATIN/CN
L1              1 E3

     FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006
L2             57 L1
L3          43283 SODIUM (L)TRANSPORT
L4              1 L2 AND L3
                S 151720-43-3/REG#

     FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006
L5              1 S 151720-43-3/RN

     FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006
L6             57 S L5
L7         200642 LUNG
L8             10 L6 AND L7
L9              7 HYDOXAM?
L10         10111 HYDROXAM?
L11             9 L3(L)L10
L12             1 L11 AND L7
L13           245 .D HIS
L14            85 L10(L)L7
L15         52885 LETHAL
L16            24 L10(L)L15
L17         92484 POISON?
L18            24 L10(L)L17

     FILE 'REGISTRY' ENTERED AT 10:12:54 ON 21 SEP 2006
                E TRICHOSTATIN/CN
L19             1 E3
L20             0 FIOLE CAPLUS

     FILE 'CAPLUS' ENTERED AT 10:14:03 ON 21 SEP 2006
L21            58 L19

=> l7 and l21
L22             5 L7 AND L21

=> d l22 1-5 ti

L22  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Aberrant methylation of the eyes absent 4 gene in ulcerative
     colitis-associated dysplasia

L22  ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Regulation of the p21 gene and uses thereof

L22  ANSWER 3 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Treatment of lung cells with histone deacetylase inhibitors

L22  ANSWER 4 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   A preparation of unsaturated hydroxamic acid derivatives useful as histone
     deacetylase inhibitors

L22  ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis
     Involves the Transcriptional Activation of NF-κB through the Akt
     Pathway


=> d l22 5 ti fbib abs

L22  ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
```

TI Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis Involves the Transcriptional Activation of NF-κB through the Akt Pathway
AN 2003:380703 CAPLUS
DN 139:127585
TI Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis Involves the Transcriptional Activation of NF-κB through the Akt Pathway
AU Mayo, Marty W.; Denlinger, Chadrick E.; Broad, Robert M.; Yeung, Fan; Reilly, Eugene T.; Shi, Yang; Jones, David R.
CS Dep. Surg., Univ. Virginia, Charlottesville, VA, 22908, USA
SO Journal of Biological Chemistry (2003), 278(21), 18980-18989
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer agents for the treatment of solid and hematol. malignancies. Although HDAC inhibitors induce cell death through an apoptotic process, little is known about the mol. events that control their effectiveness. In this study, we demonstrate that HDAC inhibitors are limited in their ability to induce apoptosis in non-small cell lung cancer (NSCLC) cell lines despite their ability to effectively inhibit deacetylase activity. Because the anti-apoptotic transcription factor NF-κB has been shown to be under the control of HDAC-mediated repression, we analyzed whether HDAC inhibitors activated NF-κB in NSCLC cells. HDAC inhibitors effectively stimulated endogenous NF-κB-dependent gene expression by up-regulating IL-8, Bcl-XL, and MMP-9 transcripts. The ability of HDAC inhibitors to increase NF-κB transcriptional activity was not associated with signaling events that stimulated nuclear translocation, but rather modulated the transactivation potential of the RelA/p65 subunit of NF-κB. The inhibition of HDAC activity was associated with the recruitment of the p300 transcriptional co-activator to chromatin in an Akt-dependent manner. Moreover, Akt directly phosphorylated p300 in vitro and was required for stimulating the transactivation potential of the co-activator following the addition of HDAC inhibitors. Selective inhibition of either the phosphoinositide 3-kinase/Akt pathway, or NF-κB itself blocked the ability of HDAC inhibitors to activate NF-κB and dramatically sensitized NSCLC cells to apoptosis following of the addition of HDAC inhibitors. Our study indicates that the ineffectiveness of HDAC inhibitors to induce apoptosis in NSCLC cancer cells is associated with the ability of these mols. to stimulate NF-κB-dependent transcription and cell survival.
RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> oxyamide
19 OXYAMIDE
10 OXYAMIDES
L23 27 OXYAMIDE
(OXYAMIDE OR OXYAMIDES)

=> d l23 20-27 ti

L23 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Irreversible enzyme inhibitors. CLXXIX. Active-site-directed irreversible enzyme inhibitors of dihydrofolate reductase from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with oxyamide bridges to a terminal sulfonyl fluoride

L23 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI New type of stable tetrapolar phosphorus ylide

L23 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Kinetics of the formation of aluminum oxyamide by ammonolysis of the oxychloride

L23 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Infrared spectroscopic study of the oxyamide and thioamide of aluminum

L23 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Flavone-7-oxyacetamides

L23 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI A new compound of trivalent iron: the oxyamide FeO(NH2)

L23 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effect of non-ionic demulsifying agents on the desalting of Romashkino crude oil

L23 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Aminoplasts containing silicon

=> d l23 1-19 ti

L23 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Photosensitive composition and lithographic printing plate precursor

L23 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment of lung cells with histone deacetylase inhibitors

L23 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Production L-α-oxy acids by enzymic resolution

L23 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Bactericidal antimicrobial methods and compositions using acyl hydrazides, oxyamides, and 8-hydroxyquinolines as antibiotic potentiators for treatment of Gram-positive infections

L23 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synthesis of N-benzyl-indolyl(benzyloxy)amido derivatives as PDE-IV inhibitors

L23 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Manufacture of optically-active oxyamines by enzymic stereoselective hydrolysis of oxyamides

L23 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Water- and hydroxyl group-free gels and xerogels based on a network of oxygen-bridged metal and/or semimetal atoms, and their manufacture and use

L23 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synthesis of an oxyamide linked nucleotide dimer and incorporation into antisense oligonucleotide sequences

L23 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI The thermal transformation of aromatic amides

L23 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI The thermal transformation of an aromatic poly(amide), poly(ortho-oxyamide) and poly(benzoxazole)

L23 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN

TI Reaction of benzohydroxamic acid with N-glycidyl-N-ethylaniline

L23 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI New dihydrazido and oxyamido derivatives of phosphoric and thiophosphoric acid with bis(2-chloroethyl)amido substituents

L23 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Synthesis of fluorescent peptidyl thioneamides and the assay of papain in the presence of trypsin

L23 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Oxyamides and their use as fungicides

L23 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Basic methanolysis of N-aryl-N-methylthiobenzamides

L23 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Heat-resisting film

L23 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Polymer compositions for films

L23 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Heat-resistant polyimides or -imidazopyrrolones

L23 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Molecular weight determination of benzene-containing compounds by ultraviolet spectrometry

=> d l23 14 ti fbib abs

L23 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Oxyamides and their use as fungicides
AN 1982:455463 CAPLUS
DN 97:55463
TI N-Oxyamides and their use as fungicides
IN Stetter, Joerg; Fuehrer, Wolfgang; Brandes, Wilhelm
PA Bayer A.-G. , Fed. Rep. Ger.
SO Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | EP 46931 | A2 | 19820310 | EP 1981-106468 | | 19810820 |
| | EP 46931 | A3 | 19820317 | | | |
| | R: AT, BE, CH, DE, FR, GB, IT, NL, SE | | | | | |
| | | | | DE 1980-3033160 | A | 19800903 |
| | DE 3033160 | A1 | 19820422 | DE 1980-3033160 | | 19800903 |
| | JP 57077650 | A2 | 19820515 | JP 1981-136223 | | 19810901 |
| | | | | DE 1980-3033160 | A | 19800903 |
| | DK 8103879 | A | 19820304 | DK 1981-3879 | | 19810902 |
| | | | | DE 1980-3033160 | A | 19800903 |
| | AU 8174864 | A1 | 19820311 | AU 1981-74864 | | 19810902 |
| | | | | DE 1980-3033160 | A | 19800903 |
| | BR 8105613 | A | 19820518 | BR 1981-5613 | | 19810902 |
| | | | | DE 1980-3033160 | | 19800903 |
| | ES 505137 | A1 | 19820816 | ES 1981-505137 | | 19810902 |
| | | | | DE 1980-3033160 | A | 19800903 |
| | ZA 8106082 | A | 19820825 | ZA 1981-6082 | | 19810902 |
| | | | | DE 1980-3033160 | A | 19800903 |

GI




I




II

AB Amides I [R1 = H, alkyl, halo; R2, R3, R4 = H, alkyl; R5, R6 = H, halogen (un)substituted aliphatic group; R5R6 = alkylene; R7 = furyl, thienyl, tetrahydrofuryl, tetrahydrothienyl, aliphatic group (un)substituted with halogen, cyano, or thiocyanato, CH2R (R = pyrazolyl, 1,2,4-triazolyl, imidazolyl), CH2OR8 [R8 = (un)substituted aliphatic group or alkoxyalkyl], CH2SR8, OR8, SR8, CH2OSO2R8, CO2R8, tetrahydropyranyloxymethyl], useful as agricultural fungicides (no data), were prepared Thus, treating 2,6-Me2C6H3N(COCH2OMe)CHMeCO2H and MeONH2.HCl containing NEt3 in CH2Cl2 with dicyclohexylcarbodiimide gave 36% 2,6-Me2C6H3N(COCH2OMe)CHMeCONHOMe which was methylated with Me2SO4 in 50% NaOH-PhMe containing PhCH2N+Et3.Cl- to give 45% amide II.

```
=> airway epithelial
         21836 AIRWAY
          9399 AIRWAYS
         25960 AIRWAY
                 (AIRWAY OR AIRWAYS)
        106608 EPITHELIAL
             8 EPITHELIALS
        106612 EPITHELIAL
                 (EPITHELIAL OR EPITHELIALS)
L24       2371 AIRWAY EPITHELIAL
                 (AIRWAY(W)EPITHELIAL)

=> d his

     (FILE 'HOME' ENTERED AT 09:00:46 ON 21 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 09:01:11 ON 21 SEP 2006
                 E OXAMFLATIN/CN
L1             1 E3

     FILE 'CAPLUS' ENTERED AT 09:01:51 ON 21 SEP 2006
L2            57 L1
L3         43283 SODIUM (L)TRANSPORT
L4             1 L2 AND L3
                 S 151720-43-3/REG#

     FILE 'REGISTRY' ENTERED AT 09:15:23 ON 21 SEP 2006
L5             1 S 151720-43-3/RN

     FILE 'CAPLUS' ENTERED AT 09:15:23 ON 21 SEP 2006
L6            57 S L5
L7        200642 LUNG
L8            10 L6 AND L7
L9             7 HYDOXAM?
L10        10111 HYDROXAM?
L11            9 L3(L)L10
L12            1 L11 AND L7
```

```
L13          245 .D HIS
L14           85 L10(L)L7
L15        52885 LETHAL
L16           24 L10(L)L15
L17        92484 POISON?
L18           24 L10(L)L17

     FILE 'REGISTRY' ENTERED AT 10:12:54 ON 21 SEP 2006
                E TRICHOSTATIN/CN
L19            1 E3
L20            0 FIOLE CAPLUS

     FILE 'CAPLUS' ENTERED AT 10:14:03 ON 21 SEP 2006
L21           58 L19
L22            5 L7 AND L21
L23           27 OXYAMIDE
L24         2371 AIRWAY EPITHELIAL

=> l10 and l24
L25            1 L10 AND L24

=> l3 and l25
L26            0 L3 AND L25

=> logoff hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               29.71     211.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -1.50     -12.75

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:24:26 ON 21 SEP 2006

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 10:44:44 ON 21 SEP 2006
FILE 'CAPLUS' ENTERED AT 10:44:44 ON 21 SEP 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               29.71     211.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -1.50     -12.75

=> logoff hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               30.17     212.32
```

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -1.50     -12.75

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:45:06 ON 21 SEP 2006

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  5  MAY 11   KOREAPAT updates resume
 NEWS  6  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  7  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  8  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS  9  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 10  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 11  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 12  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 13  JUl 14   FSTA enhanced with Japanese patents
 NEWS 14  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 15  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS 16  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS 17  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS 18  SEP 11   CA/CAplus enhanced with more pre-1907 records
 NEWS 19  SEP 21   CA/CAplus fields enhanced with simultaneous left and right
                   truncation

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
```

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:04:22 ON 21 SEP 2006

=> logoff hold

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:04:44 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HOME' AT 12:09:55 ON 21 SEP 2006
FILE 'HOME' ENTERED AT 12:09:55 ON 21 SEP 2006

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 12:10:08 ON 21 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4
DICTIONARY FILE UPDATES: 20 SEP 2006 HIGHEST RN 908067-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer
be available. Please contact CAS Customer Care
(http://www.cas.org/supp.html) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10715377\10715377 arylalkenylhydroxamic.str



chain nodes :
7 8 9 10 11 12 13 14
ring nodes :
1 2 3 4 5 6
chain bonds :
5-7 7-8 8-9 9-10 10-11 11-12 11-13 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
11-12 11-13
exact bonds :
5-7 7-8 8-9 9-10 10-11 12-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam

SAMPLE SEARCH INITIATED 12:10:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 226 TO ITERATE

100.0% PROCESSED 226 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3619 TO 5421
PROJECTED ANSWERS: 1674 TO 2966

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, 3-[2,3-dihydro-1-[[2-(1H-indol-3-yl)ethyl][[4-(4-morpholinylcarbonyl)-1H-pyrrol-2-yl]methyl]amino]-1H-inden-5-yl]-N-hydroxy-, (2E)- (9CI)
MF C32 H35 N5 O4

Double bond geometry as shown.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> 0
L3 853427 0

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10715377\10715377 fixedHarylalkenylhydrox.str



chain nodes :
7 8 9 10 11 12 13 14
ring nodes :
1 2 3 4 5 6
chain bonds :
5-7 7-8 8-9 9-10 10-11 11-12 11-13 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
11-12 11-13
exact bonds :
5-7 7-8 8-9 9-10 10-11 12-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
1:>= minimum 1 2:>= minimum 1 3:>= minimum 1 4:>= minimum 1 6:>= minimum 1
7:>= minimum 1 8:>= minimum 1 9:>= minimum 1 10:>= minimum 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR




Structure attributes must be viewed using STN Express query preparation.

=> search l4 sss sam
SAMPLE SEARCH INITIATED 12:13:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 226 TO ITERATE

100.0% PROCESSED 226 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3619 TO 5421
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> search l4 sss full
FULL SEARCH INITIATED 12:13:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4438 TO ITERATE

100.0% PROCESSED 4438 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.01

L6 11 SEA SSS FUL L4

=> d scan

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl-, monosodium salt (9CI)
MF C9 H9 N O2 . Na



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):11

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Pentadienamide, N-hydroxy-5-phenyl-, (2E,4E)- (9CI)
MF C11 H11 N O2

Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6-Heptatrienamide, N-hydroxy-7-phenyl- (9CI)
MF C13 H13 N O2



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl-, monopotassium salt (9CI)
MF C9 H9 N O2 . K



L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl-, compd. with N-[2-[(4-amino-3-methylphenyl)ethylamino]ethyl]methanesulfonamide (1:1) (9CI)
MF C12 H21 N3 O2 S . C9 H9 N O2

CM 1



CM 2



L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl-, (2E)- (9CI)
MF C9 H9 N O2

Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl- (9CI)
MF C9 H9 N O2
CI COM



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4,6-Heptatrienamide, N-hydroxy-7-phenyl-, (2E,4E,6E)- (9CI)
MF C13 H13 N O2

Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Pentadienamide, N-hydroxy-5-phenyl- (9CI)
MF C11 H11 N O2



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl-, (Z)- (9CI)
MF C9 H9 N O2

Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L6 11 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl-, calcium salt (2:1) (9CI)
MF C9 H9 N O2 . 1/2 Ca





ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 173.90 | 174.11 |

FILE 'CAPLUS' ENTERED AT 12:13:53 ON 21 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> l6
L7 104 L6

=> asthma or bronchitis or COPD

```
          32308 ASTHMA
             21 ASTHMAS
          32316 ASTHMA
                (ASTHMA OR ASTHMAS)
           5800 BRONCHITIS
           2762 COPD
             15 COPDS
           2775 COPD
                (COPD OR COPDS)
L8        37979 ASTHMA OR BRONCHITIS OR COPD

=> l7 and l8
L9            3 L7 AND L8

=> d l9 n1-3 ti fbib abs
'N1-3' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
```

structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):e4nd
'E4ND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its

```
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):\end
'\END' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
```

structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d l9 1-3 ti fbib abs

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
AN 2005:1168848 CAPLUS
DN 143:446691
TI Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
IN Franke, Hanshermann; Lennartz, Peter; Maurer, Alexander, B.; Hentsch, Bernd; Hoevelmann, Sascha; Martin, Elke
PA G2M Cancer Drugs A.-G., Germany; Desitin Arzneimittel G.m.b.H.
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 1591109 | A1 | 20051102 | EP 2004-10333 | 20040430 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | WO 2005105055 | A1 | 20051110 | WO 2005-EP4739 | 20050502 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | | EP 2004-10333 | A 20040430 |

OS MARPAT 143:446691
AB The present invention relates to an orally available galenics formulation of Valproic Acid or derivs. thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum inhibition of histone deacetylases in a therapeutic setting. This specific galenics formulation is designed for the treatment of malignant diseases and diseases associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect, e.g., by induction of differentiation and/or apoptosis. Due to the bi-phasic release pattern the resulting pharmacokinetic profile is able to inhibit HDAC target enzymes most efficiently and to subsequently induce histone hyperacetylation in a rapid

as well as a long-lasting fashion. This profile secures the efficient modulation of a desired target gene expression profile which contributes to the therapeutic benefit.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment of lung cells with histone deacetylase inhibitors
AN 2004:701812 CAPLUS
DN 141:167803
TI Treatment of lung cells with histone deacetylase inhibitors
IN Wiech, Norbert L.; Lan-Hargest, Hsuan-Yin
PA USA
SO U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 25,947.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | US 2004167184 | A1 | 20040826 | US 2003-715377 | | 20031119 |
| | | | | US 2001-812940 | B1 | 20010327 |
| | | | | US 2001-25947 | A2 | 20011226 |
| | | | | US 2002-427567P | P | 20021120 |
| | US 2002143037 | A1 | 20021003 | US 2001-25947 | | 20011226 |
| | | | | US 2001-812940 | B1 | 20010327 |

PATENT FAMILY INFORMATION:
FAN 2002:754352

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | | 20020325 |
| | WO 2002076941 | A3 | 20040212 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2001-812940 | A1 | 20010327 |
| | | | | US 2001-812944 | A1 | 20010327 |
| | | | | US 2001-812945 | A1 | 20010327 |
| | | | | US 2001-25947 | A1 | 20011226 |
| | US 2002143196 | A1 | 20021003 | US 2001-812944 | | 20010327 |
| | US 6495719 | B2 | 20021217 | | | |
| | US 2002143052 | A1 | 20021003 | US 2001-812945 | | 20010327 |
| | US 2002143037 | A1 | 20021003 | US 2001-25947 | | 20011226 |
| | | | | US 2001-812940 | B1 | 20010327 |
| | CA 2442366 | AA | 20021003 | CA 2002-2442366 | | 20020325 |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | AU 2002250401 | A1 | 20021008 | AU 2002-250401 | | 20020325 |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |

| | | | | | |
|---|---|---|---|---|---|
| | EP 1408946 | A2 | 20040421 | EP 2002-719311 | 20020325 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | | | | US 2001-812940 A | 20010327 |
| | | | | US 2001-812944 A | 20010327 |
| | | | | US 2001-812945 A | 20010327 |
| | | | | US 2001-25947 A | 20011226 |
| | | | | WO 2002-US8836 W | 20020325 |

FAN 2002:755220

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2002143052 | A1 | 20021003 | US 2001-812945 | 20010327 |
| | CA 2442366 | AA | 20021003 | CA 2002-2442366 | 20020325 |
| | | | | US 2001-812940 A | 20010327 |
| | | | | US 2001-812944 A | 20010327 |
| | | | | US 2001-812945 A | 20010327 |
| | | | | US 2001-25947 A | 20011226 |
| | | | | WO 2002-US8836 W | 20020325 |
| | WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | 20020325 |
| | WO 2002076941 | A3 | 20040212 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | | US 2001-812940 A1 | 20010327 |
| | | | | US 2001-812944 A1 | 20010327 |
| | | | | US 2001-812945 A1 | 20010327 |
| | | | | US 2001-25947 A1 | 20011226 |
| | AU 2002250401 | A1 | 20021008 | AU 2002-250401 | 20020325 |
| | | | | US 2001-812940 A | 20010327 |
| | | | | US 2001-812944 A | 20010327 |
| | | | | US 2001-812945 A | 20010327 |
| | | | | US 2001-25947 A | 20011226 |
| | | | | WO 2002-US8836 W | 20020325 |
| | EP 1408946 | A2 | 20040421 | EP 2002-719311 | 20020325 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | | | | US 2001-812940 A | 20010327 |
| | | | | US 2001-812944 A | 20010327 |
| | | | | US 2001-812945 A | 20010327 |
| | | | | US 2001-25947 A | 20011226 |
| | | | | WO 2002-US8836 W | 20020325 |
| | US 2003125306 | A1 | 20030703 | US 2002-318225 | 20021213 |
| | | | | US 2001-812945 A3 | 20010327 |
| | US 2005107348 | A1 | 20050519 | US 2004-19303 | 20041223 |
| | | | | US 2001-812945 A3 | 20010327 |
| | US 2005171208 | A1 | 20050804 | US 2005-59377 | 20050217 |
| | | | | US 2001-812945 A3 | 20010327 |

FAN 2002:755255

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2002143196 | A1 | 20021003 | US 2001-812944 | 20010327 |
| | US 6495719 | B2 | 20021217 | | |
| | CA 2442366 | AA | 20021003 | CA 2002-2442366 | 20020325 |
| | | | | US 2001-812940 A | 20010327 |
| | | | | US 2001-812944 A | 20010327 |
| | | | | US 2001-812945 A | 20010327 |

```
                                                US 2001-25947       A  20011226
                                                WO 2002-US8836      W  20020325
     WO 2002076941          A2     20021003     WO 2002-US8836          20020325
     WO 2002076941          A3     20040212
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                US 2001-812940      A1 20010327
                                                US 2001-812944      A1 20010327
                                                US 2001-812945      A1 20010327
                                                US 2001-25947       A1 20011226
     AU 2002250401          A1     20021008     AU 2002-250401          20020325
                                                US 2001-812940      A  20010327
                                                US 2001-812944      A  20010327
                                                US 2001-812945      A  20010327
                                                US 2001-25947       A  20011226
                                                WO 2002-US8836      W  20020325
     EP 1408946             A2     20040421     EP 2002-719311          20020325
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                US 2001-812940      A  20010327
                                                US 2001-812944      A  20010327
                                                US 2001-812945      A  20010327
                                                US 2001-25947       A  20011226
                                                WO 2002-US8836      W  20020325
     US 2003083521          A1     20030501     US 2002-307321          20021202
                                                US 2001-812944      A3 20010327
FAN  2004:453179
     PATENT NO.             KIND   DATE         APPLICATION NO.         DATE
     ---------------        ----   --------     --------------------    --------
PI   WO 2004046104          A2     20040603     WO 2003-US36981         20031119
     WO 2004046104          A3     20040805
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                US 2002-427567P     P  20021120
     CA 2506504             AA     20040603     CA 2003-2506504         20031119
                                                US 2002-427567P     P  20021120
                                                WO 2003-US36981     W  20031119
     AU 2003291097          A1     20040615     AU 2003-291097          20031119
                                                US 2002-427567P     P  20021120
                                                WO 2003-US36981     W  20031119
     EP 1567142             A2     20050831     EP 2003-783686          20031119
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                                US 2002-427567P     P  20021120
                                                WO 2003-US36981     W  20031119
     JP 2006508986          T2     20060316     JP 2004-553939          20031119
                                                US 2002-427567P     P  20021120
```

WO 2003-US36981 W 20031119

OS MARPAT 141:167803

AB Lung disease, such as cystic fibrosis, chronic obstructive pulmonary disease, asthma, or acute and chronic bronchitis, can be treated with an oxyamide-containing compound Preparation of e.g. 5-phenyl-2,4-pentadienoylhydroxamic acid is described.

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors

AN 2004:453179 CAPLUS

DN 141:23197

TI A preparation of unsaturated hydroxamic acid derivatives useful as histone deacetylase inhibitors

IN Wiech, Norbert L.; Lan-Hargest, Hsuan-yin

PA Circagen Pharmaceutical, USA; Beacon Laboratories

SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004046104 | A2 | 20040603 | WO 2003-US36981 | 20031119 |
| | WO 2004046104 | A3 | 20040805 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | | US 2002-427567P | P 20021120 |
| | CA 2506504 | AA | 20040603 | CA 2003-2506504 | 20031119 |
| | | | | US 2002-427567P | P 20021120 |
| | | | | WO 2003-US36981 | W 20031119 |
| | AU 2003291097 | A1 | 20040615 | AU 2003-291097 | 20031119 |
| | | | | US 2002-427567P | P 20021120 |
| | | | | WO 2003-US36981 | W 20031119 |
| | EP 1567142 | A2 | 20050831 | EP 2003-783686 | 20031119 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | | | | US 2002-427567P | P 20021120 |
| | | | | WO 2003-US36981 | W 20031119 |
| | JP 2006508986 | T2 | 20060316 | JP 2004-553939 | 20031119 |
| | | | | US 2002-427567P | P 20021120 |
| | | | | WO 2003-US36981 | W 20031119 |

PATENT FAMILY INFORMATION:

FAN 2002:754352

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | 20020325 |
| | WO 2002076941 | A3 | 20040212 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, | | | | |

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| | | | | US 2001-812940 | A1 20010327 |
| | | | | US 2001-812944 | A1 20010327 |
| | | | | US 2001-812945 | A1 20010327 |
| | | | | US 2001-25947 | A1 20011226 |
| US | 2002143196 | A1 | 20021003 | US 2001-812944 | 20010327 |
| US | 6495719 | B2 | 20021217 | | |
| US | 2002143052 | A1 | 20021003 | US 2001-812945 | 20010327 |
| US | 2002143037 | A1 | 20021003 | US 2001-25947 | 20011226 |
| | | | | US 2001-812940 | B1 20010327 |
| CA | 2442366 | AA | 20021003 | CA 2002-2442366 | 20020325 |
| | | | | US 2001-812940 | A 20010327 |
| | | | | US 2001-812944 | A 20010327 |
| | | | | US 2001-812945 | A 20010327 |
| | | | | US 2001-25947 | A 20011226 |
| | | | | WO 2002-US8836 | W 20020325 |
| AU | 2002250401 | A1 | 20021008 | AU 2002-250401 | 20020325 |
| | | | | US 2001-812940 | A 20010327 |
| | | | | US 2001-812944 | A 20010327 |
| | | | | US 2001-812945 | A 20010327 |
| | | | | US 2001-25947 | A 20011226 |
| | | | | WO 2002-US8836 | W 20020325 |
| EP | 1408946 | A2 | 20040421 | EP 2002-719311 | 20020325 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | | |
|---|---|---|---|---|---|
| | | | | US 2001-812940 | A 20010327 |
| | | | | US 2001-812944 | A 20010327 |
| | | | | US 2001-812945 | A 20010327 |
| | | | | US 2001-25947 | A 20011226 |
| | | | | WO 2002-US8836 | W 20020325 |

FAN 2002:755220

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2002143052 | A1 | 20021003 | US 2001-812945 | 20010327 |
| | CA 2442366 | AA | 20021003 | CA 2002-2442366 | 20020325 |
| | | | | US 2001-812940 | A 20010327 |
| | | | | US 2001-812944 | A 20010327 |
| | | | | US 2001-812945 | A 20010327 |
| | | | | US 2001-25947 | A 20011226 |
| | | | | WO 2002-US8836 | W 20020325 |
| | WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | 20020325 |
| | WO 2002076941 | A3 | 20040212 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| | | | | US 2001-812940 | A1 20010327 |
| | | | | US 2001-812944 | A1 20010327 |
| | | | | US 2001-812945 | A1 20010327 |
| | | | | US 2001-25947 | A1 20011226 |
| AU | 2002250401 | A1 | 20021008 | AU 2002-250401 | 20020325 |
| | | | | US 2001-812940 | A 20010327 |
| | | | | US 2001-812944 | A 20010327 |
| | | | | US 2001-812945 | A 20010327 |
| | | | | US 2001-25947 | A 20011226 |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | WO 2002-US8836 | W | 20020325 |
| | EP 1408946 | A2 | 20040421 | EP 2002-719311 | | 20020325 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | US 2003125306 | A1 | 20030703 | US 2002-318225 | | 20021213 |
| | | | | US 2001-812945 | A3 | 20010327 |
| | US 2005107348 | A1 | 20050519 | US 2004-19303 | | 20041223 |
| | | | | US 2001-812945 | A3 | 20010327 |
| | US 2005171208 | A1 | 20050804 | US 2005-59377 | | 20050217 |
| | | | | US 2001-812945 | A3 | 20010327 |

FAN 2002:755255

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | US 2002143196 | A1 | 20021003 | US 2001-812944 | | 20010327 |
| | US 6495719 | B2 | 20021217 | | | |
| | CA 2442366 | AA | 20021003 | CA 2002-2442366 | | 20020325 |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | WO 2002076941 | A2 | 20021003 | WO 2002-US8836 | | 20020325 |
| | WO 2002076941 | A3 | 20040212 | | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | | | | US 2001-812940 | A1 | 20010327 |
| | | | | US 2001-812944 | A1 | 20010327 |
| | | | | US 2001-812945 | A1 | 20010327 |
| | | | | US 2001-25947 | A1 | 20011226 |
| | AU 2002250401 | A1 | 20021008 | AU 2002-250401 | | 20020325 |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | EP 1408946 | A2 | 20040421 | EP 2002-719311 | | 20020325 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| | | | | US 2001-812940 | A | 20010327 |
| | | | | US 2001-812944 | A | 20010327 |
| | | | | US 2001-812945 | A | 20010327 |
| | | | | US 2001-25947 | A | 20011226 |
| | | | | WO 2002-US8836 | W | 20020325 |
| | US 2003083521 | A1 | 20030501 | US 2002-307321 | | 20021202 |
| | | | | US 2001-812944 | A3 | 20010327 |

FAN 2004:701812

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | US 2004167184 | A1 | 20040826 | US 2003-715377 | | 20031119 |
| | | | | US 2001-812940 | B1 | 20010327 |

| | | | | | |
|---|---|---|---|---|---|
| | | | | US 2001-25947 | A2 20011226 |
| | | | | US 2002-427567P | P 20021120 |
| US 2002143037 | | A1 | 20021003 | US 2001-25947 | 20011226 |
| | | | | US 2001-812940 | B1 20010327 |

OS MARPAT 141:23197

GI



I

AB The invention relates to a preparation of amides of formula I [wherein: A is (hetero)cycloalk(en)yl, (hetero)aryl, etc.; Y1 and Y2 are independently selected from CH2, O, S, OC(O)O, NH, or -NHC(O)O-, etc.; L is (un)substituted C2-12 hydrocarbon chain optionally containing one double bond, at least one triple bond, or at least one double bond and one triple bond; R1 is H, alk(en/yn)yl, alkoxy, OH, etc.; R2 is H, alkyl, hydroxyalkyl, or haloalkyl, etc.], useful as histone deacetylase inhibitors. The invented compds. are claimed to be useful for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and asthma, etc. The prepared compds. were screened in cystic fibrosis assay (example 4 and 5) and for bronchial epithelial electrolyte transport (example 6). The mean inhibition of sodium transport for 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was 69.2%. Inhibition of sodium transport by 7-phenyl-2,4,6-heptatrienoylhydroxamic acid was concentration-dependent with a half-maximal inhibitory concentration of 11.9 μM. For instance, PhCH:CHCH:CHC(O)NHOH was prepared from PhCH:CHCH:CHCO2H and NH2OH•HCl in anhydrous DMF (example 2, no yield data).

=> logoff hold

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 29.45 | 203.56 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -2.25 | -2.25 |

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:16:28 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 12:39:47 ON 21 SEP 2006
FILE 'CAPLUS' ENTERED AT 12:39:47 ON 21 SEP 2006


| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
|---|---|---|

```
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     29.45     203.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)         SINCE FILE      TOTAL
                                                        ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -2.25      -2.25

=> logoff hold
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     29.91     204.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)         SINCE FILE      TOTAL
                                                        ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -2.25      -2.25

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:40:39 ON 21 SEP 2006

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 12:41:06 ON 21 SEP 2006
FILE 'CAPLUS' ENTERED AT 12:41:06 ON 21 SEP 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                     30.37     204.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)         SINCE FILE      TOTAL
                                                        ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -2.25      -2.25

=> d his

     (FILE 'HOME' ENTERED AT 12:04:22 ON 21 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 12:10:08 ON 21 SEP 2006
L1             STRUCTURE UPLOADED
L2            50 SEARCH L1 SSS SAM
L3        853427 0
L4             STRUCTURE UPLOADED
L5             0 SEARCH L4 SSS SAM
L6            11 SEARCH L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:13:53 ON 21 SEP 2006
L7           104 L6
L8         37979 ASTHMA OR BRONCHITIS OR COPD
L9             3 L7 AND L8

=> save temp l7 hydroxamfinds/a
HYDROXAMFINDS/A IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list.  The name must:
```

```
  1. Begin with a letter,
  2. Have 1-12 characters,
  3. Contain only letters (A-Z) and numbers (0-9),
  4. End with /Q for a query (search profile,
     structure, or screen set), /A for an answer
     set, or /L for an L-number list.
  5. Not already be in use as a saved name,
  6. Not be END, SAV, SAVE, SAVED
  7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):hdrxamfnds/a
ANSWER SET L7 HAS BEEN SAVED AS 'HDRXAMFNDS/A'

=> sodium
       1060363 SODIUM
            35 SODIUMS
L10    1060372 SODIUM
                (SODIUM OR SODIUMS)

=> transport
        708922 TRANSPORT
          5830 TRANSPORTS
L11     711245 TRANSPORT
                (TRANSPORT OR TRANSPORTS)

=> l7 and l11
L12           3 L7 AND L11

=> l12 not l9
L13           1 L12 NOT L9

=> d l13 ti fbib abs

L13  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Topical use of valproic acid, alone or with other agents, for the
     prevention or treatment of skin disorders
AN   2004:1154310  CAPLUS
DN   142:69220
TI   Topical use of valproic acid, alone or with other agents, for the
     prevention or treatment of skin disorders
IN   Pelicci, Pier Giuseppe; Minucci, Saverio; Costanzo, Antonio; Chimenti,
     Sergio; Nistico, Steven Paul; Paolino, Donatella
PA   G2M Cancer Drugs AG, Germany
SO   Eur. Pat. Appl., 40 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   EP 1491188           A1    20041229    EP 2003-14278            20030625
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     AU 2004251434         A1    20050106    AU 2004-251434           20040623
                                             EP 2003-14278        A   20030625
                                             WO 2004-EP6789       W   20040623
     AU 2004251435         A1    20050106    AU 2004-251435           20040623
                                             EP 2003-14278        A   20030625
                                             WO 2004-EP6797       W   20040623
     CA 2531101            AA    20050106    CA 2004-2531101          20040623
                                             EP 2003-14278        A   20030625
                                             WO 2004-EP6789       W   20040623
     CA 2531107            AA    20050106    CA 2004-2531107          20040623
                                             EP 2003-14278        A   20030625
```

WO 2004-EP6797 W 20040623

WO 2005000289 A1 20050106 WO 2004-EP6789 20040623

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 2003-14278 A 20030625

WO 2005000282 A2 20050106 WO 2004-EP6797 20040623

WO 2005000282 A3 20050428

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 2003-14278 A 20030625

EP 1635808 A1 20060322 EP 2004-740209 20040623

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

EP 2003-14278 A 20030625

WO 2004-EP6789 W 20040623

EP 1635798 A2 20060322 EP 2004-740216 20040623

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

EP 2003-14278 A 20030625

WO 2004-EP6797 W 20040623

US 2006160897 A1 20060720 US 2005-275258 20051221

EP 2003-14278 A 20030625

WO 2004-EP6789 A1 20040623

OS MARPAT 142:69220

AB The invention relates to a topically applicable formulation containing valproic acid or a derivative thereof which can be used alone or in combination with topically applicable formulations of retinoids or of nuclear receptor ligands, or of chemotherapeutic agents (e.g. 5-Fluorouracil). The formulation is useful for the topical treatment of cancerous skin disorders, e.g. basal cell carcinoma, squamous cell carcinoma, keratoakantoma, Bowen disease, cutaneous T-Cell lymphoma, and also for the topical treatment of premalignant lesions, and of inflammation of the skin and/or mucosa. The invention also relates to the use of this topically applicable formulation for protection from UV light and for the treatment of sunburn. The invention includes the use of valproic acid for the manufacture of a clin. used medicament for the topical treatment of the above human diseases.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 39.77 | 213.88 |

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.00      -3.00

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:44:58 ON 21 SEP 2006

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  5  MAY 11   KOREAPAT updates resume
 NEWS  6  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  7  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  8  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS  9  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 10  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 11  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 12  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 13  JUl 14   FSTA enhanced with Japanese patents
 NEWS 14  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 15  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS 16  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS 17  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS 18  SEP 11   CA/CAplus enhanced with more pre-1907 records
 NEWS 19  SEP 21   CA/CAplus fields enhanced with simultaneous left and right
                   truncation

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
```

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:26:35 ON 21 SEP 2006

=> file caplus
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'CAPLUS' ENTERED AT 14:26:47 ON 21 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 21 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 20 Sep 2006 (20060920/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> leukotriene
         13967 LEUKOTRIENE
          7800 LEUKOTRIENES
L1       16083 LEUKOTRIENE
                (LEUKOTRIENE OR LEUKOTRIENES)

=> sodium(l)transport
       1060363 SODIUM
            35 SODIUMS
       1060372 SODIUM
                (SODIUM OR SODIUMS)
        708922 TRANSPORT
          5830 TRANSPORTS
        711245 TRANSPORT
                (TRANSPORT OR TRANSPORTS)
L2       43283 SODIUM(L)TRANSPORT

=> l1(l)l2
L3          26 L1(L)L2

=> d l3 20-26 ti

L3   ANSWER 20 OF 26 CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Regulation of renal transport processes and hemodynamics by macrophages
     and lymphocytes

L3   ANSWER 21 OF 26  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Studies on the uptake, binding and metabolism of leukotriene B4 by human
```

neutrophils

L3 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
TI Sodium/hydrogen ion exchange modulates the production of leukotriene B4 by human neutrophils

L3 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
TI Leukotriene D4-induced increases in the cytoplasmic pH of human myelocytic leukocytes

L3 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
TI Electrophysiological consequences of leukotrienes applied on isolated rat retina

L3 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
TI The effect of cyclic nucleotides and eicosanoids on sodium and potassium transport in human red cells

L3 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
TI Similarities in the mechanisms by which formyl-methionyl-leucyl-phenylalanine, arachidonic acid and leukotriene B4 increase calcium and sodium influxes in rabbit neutrophils

=> epitheliumj
0 EPITHELIUMJ
L4 0 EPITHELIUMJ

=> epithelium
98761 EPITHELIUM
83 EPITHELIUMS
12896 EPITHELIA
L5 104174 EPITHELIUM
(EPITHELIUM OR EPITHELIUMS OR EPITHELIA)

=> l3 and l5
L6 1 L3 AND L5

=> d l6 ti fbib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Modulation of ion transport in cultured rabbit tracheal epithelium by lipoxygenase metabolites
AN 1993:33455 CAPLUS
DN 118:33455
TI Modulation of ion transport in cultured rabbit tracheal epithelium by lipoxygenase metabolites
AU Egan, M. E.; Wagner, M. H.; Zeitlin, P. L.; Guggino, W. B.
CS Sch. Med., Johns Hopkins Univ., Baltimore, MD, USA
SO American Journal of Respiratory Cell and Molecular Biology (1992), 7(5), 500-6
CODEN: AJRBEL; ISSN: 1044-1549
DT Journal
LA English
AB Lipoxygenase metabolites influence ion movement and fluid balance in the airways. The effects of nordihydroguaiaretic acid (NDGA), a general inhibitor of the lipoxygenase pathway, on Na+ and Cl- secretion in cultured tracheal epithelial cells from adult rabbits were studied by short-circuit current (Isc) and radioactive tracer flux expts. NDGA inhibition of leukotriene release in freshly isolated rabbit tracheal epithelial cells was assayed by a 3H peptidyl-leukotriene RIA. At 3 μM NDGA caused a 91% reduction of leukotriene release. In unstimulated cultures, Cl- secretion (furosemide-inhibited fraction of Isc) was 11.1 μA/cm2

and was unchanged in the presence of NDGA. Epinephrine-stimulated Cl- secretion increased Isc by 12.2 μA/cm2. This stimulation was unchanged by pretreatment with NDGA, suggesting that inhibition of the lipoxygenase pathway did not affect Cl- secretion. In unstimulated cultures, Na+ absorption (amiloride-inhibited portion of Isc) was 10.7 μA/cm2 and was reduced by 79% in the presence of NDGA, suggesting that inhibition of the lipoxygenase pathway was associated with inhibition of Na+ absorption. Radioactive tracer flux expts. supported these findings. Exogenous LTD4 and LTC4 were added to cells pretreated with NDGA, and Na+ absorption was restored to 76% and 70% of control, resp. In addition, LTD4 and LTC4 were added to cells without prior inhibition of the lipoxygenase pathway to NDGA and resulted in an increase in Cl- secretion. This increase could be inhibited by pretreatment with indomethacin, an inhibitor of prostaglandin production Inhibition of the lipoxygenase pathway with NDGA is associated with a reduction in Na+ absorption, whereas addnl. LTD4 and LTC4 is associated with a stimulation of Cl- secretion. Thus, the lipoxygenase pathway has a dual effect on ion transport, modulating baseline Na+ absorption and stimulating Cl- secretion in rabbit tracheal epithelial cells.

=> logoff hold

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 18.02 | 18.23 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -0.75 | -0.75 |

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:31:02 ON 21 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | FEB 27 | New STN AnaVist pricing effective March 1, 2006 |
| NEWS 4 | MAY 10 | CA/CAplus enhanced with 1900-1906 U.S. patent records |
| NEWS 5 | MAY 11 | KOREAPAT updates resume |
| NEWS 6 | MAY 19 | Derwent World Patents Index to be reloaded and enhanced |
| NEWS 7 | MAY 30 | IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2 |
| NEWS 8 | MAY 30 | The F-Term thesaurus is now available in CA/CAplus |
| NEWS 9 | JUN 02 | The first reclassification of IPC codes now complete in INPADOC |
| NEWS 10 | JUN 26 | TULSA/TULSA2 reloaded and enhanced with new search and and display fields |
| NEWS 11 | JUN 28 | Price changes in full-text patent databases EPFULL and PCTFULL |
| NEWS 12 | JUl 11 | CHEMSAFE reloaded and enhanced |